"Designing Growth Strategies is in our DNA"

U.S. Home Infusion Therapy Market Size, Share & COVID-19 Impact Analysis, By Product (Devices, Drugs, and Services), By Indication (Anti-Infective, Chemotherapy, Hydration Therapy, Enteral Nutrition, Total Parenteral Nutrition, Immunoglobulins, and Others), and Forecast, 2021-2028

Region : USA | Format: PDF | Report ID: FBI106327

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The U.S. home infusion therapy market size was USD 16.22 billion in 2020. The market is projected to grow from USD 13.05 billion in 2021 to USD 21.65 billion in 2028 at a CAGR of 7.5% in the 2021-2028 period. The impact of COVID-19 has been unprecedented and staggering, with home-care therapy witnessing a positive impact on demand across the U.S. amid the pandemic. Based on our analysis, the market exhibited a stellar growth of 55.5% in 2020 as compared to the average year-on-year growth during 2017-2020. The fall in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.


Home infusion therapy involves the intravenous administration of drugs or biologicals to an individual at home. As an important aspect of the U.S. health care reform, healthcare provided outside of the hospital setting continues to grow. Contributing factors include aging population, the increasing prevalence of chronic diseases, and the continued pressure to reduce cost through reducing the incidence of hospitalizations and the length of hospital stay. The overarching goal of homecare is to maintain patients safely in the home setting and prevent re-hospitalizations.


Shift toward Homecare Settings amid COVID-19 Pandemic to Boost Growth


The COVID-19 pandemic had a positive impact on the market in the U.S. Key players reported significant growth in their revenues from drugs, devices, and services, owing to the significant increase in the number of patients receiving infusion therapy at home during COVID-19 restrictions.



  • For instance, Option Care Health, Inc. generated revenue of USD 3,302.6 million in 2020, and witnessed a 30.1% increase in its revenue in 2020 as compared to 2019. The growth was attributable to increase in demand for its home infusion therapy services.


Also, various new regulations aimed at providing an easy access to these services during the pandemic have contributed significantly toward the growth of home care services.



  • In October 2020, for example, Centers for Medicare & Medicaid Services announced a proposed rule expanding coverage for home infusion Durable Medical Equipment (DME), specifically for external infusion pumps, with the goal of increasing access to home infusion drugs.


Moreover, with COVID-19 outbreak, home-infusion solutions became more important than ever, allowing patients to remain in their homes, thereby reducing the risk of exposure. Hence, various local infusion service providers witnessed a surge in demand for home-based services. For instance, Arkansas-based Delta Medical Infusion witnessed 50% increase in their patient load for home infusion therapy services as compared to the previous year.


LATEST TRENDS


Request a Free sample to learn more about this report.


Expansion of Home Infusion Therapy Services to Spur Market Growth


This industry has made it possible for various types of drugs to be administered in homecare settings through a combination of pumps and professional services. The past several decades have witnessed a shift from the delivery of chemotherapy from the hospital inpatient setting to the hospital outpatient setting to the specialized community practice setting. And now, slowly and steadily, with various seismic changes and developments, homecare setting is becoming the site of care for the infusion of chemotherapy drugs.



  • In 2019, the University of Pennsylvania, Philadelphia, launched Cancer Care at Home, a pilot program for home-based chemotherapy delivered through its Penn Home Infusion Therapy program by a hospital-employed oncology-trained nurse. Within 6 months, 40 patients were treated in the pilot program. When COVID-19 outbreak led to mandatory travel restrictions, 175 patients were treated in this program in a span of 5 weeks.


Few market players have already worked on expansion of home infusion treatment in order to cater to the unmet needs of patients in the country. Currently, a few market players are conducting clinical trials for their devices to introduce novel and innovative devices in the market that will help them strengthen their foothold in the global market. For instance, in January 2021, CVS Health partnered with the Cancer Treatment Centers of America (CTCA) to offer in-home chemotherapy to cancer patients. The partnership is a significant step for at-home cancer care in the U.S., which has lagged behind compared to countries in the region.


DRIVING FACTORS


Dramatic Shift Toward Home Healthcare to Boost Market Growth


As healthcare evolves, patient care is delivered outside the hospital settings. The ageing U.S. population is the major impetus for this change in the delivery of healthcare. For instance, the U.S. census projects that by 2030, the proportion of U.S. residents older than 65 years of age will  nearly double as compared to the geriatric population in 2010 (20% vs 13%).


Healthcare agencies around the world, including those across the U.S., are focusing on the shift of patients in homecare settings to reduce the strain on healthcare settings in terms of cost and other resources. This has led to various initiatives proposed and implemented by governing agencies in the U.S., such promotion of awareness toward home care, realigning reimbursement policies for drugs, and devices, along with services for patients in homecare settings among others.


Moreover, home infusion may reduce the risk of acquiring a healthcare-associated infection since there is less patient and caregiver exposure to a hospital or clinic setting. There is an increased focus on reducing the incidence of healthcare-associated infections (HAIs) in the country, owing to huge costs associated with treatment of these infections, exerting additional economic burden on the healthcare system of the country.



  • According to the Centers for Disease Control and Prevention, HAIs are responsible for around 1.7 million infections each year in the U.S. These infections cost around USD 28 billion each year to the U.S. in direct medical costs, along with USD 12 billion in indirect costs.       


This is led to a rise in number of patients opting for infusion therapy at home. This trend has been further fueled by the pandemic, leading to a significant rise in number of patients availing these services in the U.S. in 2020.


RESTRAINING FACTORS


Perceived Safety Concerns Coupled with Resistance among Patient Population to Hamper Market Growth


Despite the patient population served by home infusion treatment is large and growing, there are certain factors that are restricting the U.S. home infusion therapy market growth during the forecast period. One such factor is the safety concerns associated with the therapy. Both patient and physicians are concerned about the potential risk of adverse events during infusion and general drug toxicity. This can be attributed to the lack of direct physician presence in the home setting. Moreover, the risk management is especially problematic in home care since all the necessary health care workplace protections for both workers and patients may not be in place or readily available. Furthermore, unsanitary conditions are a special concern, since the spread of infectious disease within the household is well documented, and various procedures in home care could present a risk of infection.


On the other hand, patients and physicians will often base their preference for a setting on experience. Real or perceived technical hurdles are greater for unfamiliar settings of care. Adoption of home infusion therapy for certain conditions such as cancer among the patient population is lower owing to the patients’ preference toward the cost effective treatment in hospital setting.


Therefore, the above mentioned factors coupled with the presence of limited reimbursement scenario is anticipated to hamper the market growth during the forecast period.


SEGMENTATION


By Product Analysis


To know how our report can help streamline your business, Speak to Analyst


Increasing Number of Regulatory Approvals for Infusion Drugs to Support Dominance of Drugs Segment


Based on product, the U.S. market is segmented into devices, drugs, and services


Drugs accounted for a dominating market share in 2020. Increasing number of regulatory approvals for infusion drugs coupled with a robust pipeline of leading players, is primarily responsible for its highest market share during the forecast period. For instance, in June 2021, the Food and Drug Administration approved Biogen’s Alzheimer’s disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer’s. Moreover, the increasing prevalence of chronic and acute diseases such as cancer, hemophilia, autoimmune diseases, immune deficiencies, multiple sclerosis, rheumatoid arthritis, etc., in the U.S. and shift toward homecare settings for infusion therapy, is fueling the growth of the segment.


On the other hand, services segment is anticpated to grow wth the highest growth rate during the forecast timeframe. Robust efforts by market players and healthcare organizations to provide home infusion therapy services for a large number of disease indications is primarily responsible for the segmental growth during the forecast period.


By Indication Analysis


Higher Prevalence of Gastrointestinal Disorders is Responsible for Higher Share of the Enteral Nutrition Segment


Based on indication, the U.S. market is categorized into anti-infective, chemotherapy, hydration therapy, enteral nutrition, total parenteral nutrition, immunoglobulins, and others.


The enteral nutrition segment held the lion’s share in 2020. The dominance is attributable to the increasing prevalence of gastrointestinal disorders, diabetes ad other complications requiring enteral nutrition in the U.S. For instance, according to research article published by NCBI, the prevalence of home enteral nutrition (HEN) in the United States is 4 to 10 times higher than in other Western countries.


Anti-infective is estimated to be the second most dominant indication by the end of 2028. The growth is attributable  to the higher prevalence of infectious diseases, increasing number anti-infective drugs approvals in oral medication segment, ease of set-up for anti-infective infusion therapy, and its low cost.


KEY INDUSTRY PLAYERS


Strong Product Portfolio of Leading Players Aid in Their Dominance


The U.S. market is a semi-consolidated market with top players, such as Option Care Health, Inc., CVS Health, and Optum, Inc. (UnitedHealth Group), comprising major portion of the U.S. market. These major players are constantly focusing on product launches with various technological advancements for home infusion treatment and entering into strategic partnership with other players in order to expand their product portfolio.



  • For instance, in August 2019, Option Care Enterprises, Inc. and BioScrip, Inc. collaborated to form a new combined company, Option Care Health, Inc. which emerged as the largest independent home and alternate site infusion services provider in the U.S.


Other prominent players include Infusystem, CareCentrix, Inc., KabaFusion, and others.


LIST OF KEY COMPANIES PROFILED :



  • Option Care Health Inc. (Illinois, U.S.)

  • Optum, Inc. (Eden Prairie, U.S.)

  • CareCentrix, Inc. (Hartford, U.S.)

  • CVS Health (Woonsocket, Rhode Island, U.S.)

  • KabaFusion (Cerritos, U.S.)

  • PromptCare (New Jersey, U.S.)

  • Baxter International Inc. (Deerfield, U.S.)

  • Infusystem (Michigan, U.S.)


KEY INDUSTRY DEVELOPMENTS:



  • January 2021 – Option Care Health Inc. partnered with Louisiana-based home health service provider, Amedisys Inc., to deliver COVID-19 infusion therapy to the vulnerable population.

  • February 2020 –Avoset developed a homecare system, AvosetGO, an infusion pump device with embedded touch screens which can be connected and watched over via smart devices.


REPORT COVERAGE


An Infographic Representation of U.S. Home Infusion Therapy Market

To get information on various segments, share your queries with us



The U.S. home infusion therapy market research report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, product type, and indication. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market over recent years.


Report Scope & Segmentation














































  ATTRIBUTE



  DETAILS



Study Period



2017-2028



Base Year



2020



Estimated Year



 2021



Forecast Period



2021-2028



Historical Period



2017-2019



Unit



Value (USD Billion)



Segmentation



Product and Indication



By Product




  • Devices

  • Drugs

  • Services



By Indication


 




  • Anti-Infective

  • Chemotherapy

  • Hydration Therapy

  • Enteral Nutrition

  • Total Parenteral Nutrition

  • Immunoglobulins

  • Others



Frequently Asked Questions

Fortune Business Insights says that the U.S. market stood at USD 16.22 billion in 2020 and is projected to reach USD 21.65 billion by 2028.

Perceived safety concerns coupled with resistance among patient population to hamper the market growth

The market will exhibit steady growth at a CAGR of 7.5% during the forecast period (2021-2028).

By product, the drugs segment is the leading segment.

Economic and clinical benefits of home infusion therapy surge the demand for these services across the U.S.

Option Care Health, Inc., CVS Health, and Optum, Inc. (UnitedHealth Group) are some of the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • Feb, 2022
  • 2020
  • 2017-2019
  • 74

    CHOOSE LICENSE TYPE

  • $2850
    $3850
    $5250

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Grifols
Jubilant
Galemed
abbvie
Styker

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X